Fundamental Research Keeps Their Buy Rating on Yorkton Equity Group Inc (YEG)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Rajeev is an analyst with an average return of -9.1% and a 35.28% success rate. Rajeev covers the Basic Materials sector, focusing on stocks such as Fortune Minerals, Silver X Mining, and Power Metallic Mines Inc.
Currently, the analyst consensus on Yorkton Equity Group Inc is a Moderate Buy with an average price target of C$0.37.
The company has a one-year high of C$0.22 and a one-year low of C$0.16. Currently, Yorkton Equity Group Inc has an average volume of 17.03K.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
16 minutes ago
- Business Insider
Candel Therapeutics initiated with a Buy at Brookline
Brookline analyst Kemp Dolliver initiated coverage of Candel Therapeutics (CADL) with a Buy rating and $25 price target Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies, the analyst tells investors in a research note. The firm says the company's lead candidate CAN-2409 met the primary endpoint in a Phase 3 trial in newly-diagnosed localized prostate cancer in intermediate- or high-risk patients, setting the stage for an application filing in Q4 of 2026. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
16 minutes ago
- Business Insider
Krystal Biotech price target raised to $176 from $155 at Citi
Citi raised the firm's price target on Krystal Biotech (KRYS) to $176 from $155 and keeps a Neutral rating on the shares. KB801 is an underappreciated asset that may be able to show differentiation from commercial Oxervate given its 's better dosing regimen and potentially superior NGF protein duration, and the firm has incorporated the KB801 program into its model, assigning it a 25% probability of success, the analyst tells investors in a research note. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
16 minutes ago
- Business Insider
Piper Sandler pharmaceuticals analyst holds analyst/industry conference call
Pharmaceuticals analysts sizes up the data for Corcept Therapeutics (CORT)' Relacorilant in ovarian cancer on an Analyst/Industry conference call to be held on July 10. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
